Fetuin-A as a Biomarker for Diabetic Nephropathy: Insights and Clinical Implications

Abstract

Diabetic nephropathy (DN) remains one of the leading causes of end-stage renal disease globally, representing a major microvascular complication of diabetes mellitus. Early detection and intervention are critical for slowing disease progression and reducing morbidity and mortality. In recent years, the hepatokine glycoprotein Fetuin-A has emerged as a potential biomarker for DN, providing insights into its pathophysiological role in kidney damage among diabetic patients. Fetuin-A, primarily produced in the liver, plays a dual role in metabolic regulation and inflammation, both of which are central mechanisms in the development of DN. Elevated serum Fetuin-A levels have been associated with insulin resistance, chronic inflammation, and vascular calcification, all of which contribute to the progression of diabetic kidney disease. Recent studies have demonstrated a significant correlation between increased Fetuin-A levels and renal function, albuminuria, and declining glomerular injury in patients with type 2 diabetes mellitus (T2DM). Additionally, Fetuin-A interacts with key signaling pathways, including the insulin signaling cascade and inflammatory cytokines, which are implicated in the pathogenesis of DN. Its ability to modulate mineral metabolism and prevent ectopic calcification in the kidneys further highlights its complex role in renal health and disease. Despite promising findings, the exact mechanistic pathways linking Fetuin-A to DN remain incompletely understood. Some studies have reported conflicting results, suggesting the possibility of context-dependent effects of Fetuin-A depending on the stage of diabetes and nephropathy. This underscores the need for further longitudinal studies and larger patient cohorts to validate Fetuin-A as a reliable biomarker for DN diagnosis, disease monitoring, and therapeutic targeting. Clinically, the measurement of serum Fetuin-A levels could provide an additional tool for risk stratification and early intervention in diabetic patients predisposed to nephropathy. Furthermore, targeting Fetuin-A-related pathways may open novel therapeutic avenues to mitigate renal injury in diabetic individuals.

This review aims to summarize the current evidence regarding the association between Fetuin-A and diabetic nephropathy, elucidate its biological roles in disease progression, and explore its potential utility as a biomarker and therapeutic target. Future research directions and clinical implications are also discussed to provide a comprehensive understanding of Fetuin-A's role in diabetic kidney disease.